ERA Test Explained: When Should Couples with Failed IVF Take It?

What Does the ERA Test Actually Do?

Patients who hear “endometrial receptivity analysis” assume the test can tell them why their embryo did not implant. It cannot. What it does is narrower than that. It takes a snapshot of gene expression in the uterine lining on one specific day of one specific cycle and predicts whether the timing of progesterone exposure has made the endometrium receptive at the moment the biopsy was taken.

• The biopsy itself: During a hormone replacement mock cycle identical to the one used for a frozen transfer, a thin catheter collects a small sample of endometrial tissue on the day the embryo would normally be transferred. It takes about 30 seconds. It feels like a sharp period cramp. The sample goes to a lab that reads 248 genes and reports back receptive, pre-receptive, or post-receptive.
• What non-receptive means: About a third of patients get told their window is displaced, meaning the endometrium was not ready for an embryo at the standard progesterone timing. The recommendation is to shift the transfer by 12 or 24 hours in the next cycle. That sounds logical. The part nobody emphasises enough is that no RCT has proven this timing shift actually results in more live births.
• One cycle, one snapshot: The ERA result comes from one biopsy in one cycle, and there is published evidence that the window of implantation can shift between cycles in the same woman, which means a result that said pre-receptive in March might have been receptive in April without changing anything. This variability is the fundamental weakness patients are rarely told about before paying for the test.
• Cost and delay: ERA costs 15,000 to 40,000 rupees in India, requires an entire mock cycle before the actual transfer cycle, and adds 4 to 6 weeks to the timeline. For couples who have already been through multiple failed cycles and are financially and emotionally stretched, that additional cycle of hormone preparation just for a biopsy carries a weight that the clinic’s intake form does not capture.

Women considering ERA as part of their IVF treatment in India plan should know what the test measures and what it does not before committing to an extra cycle and the associated cost.

Does ERA Actually Improve IVF Success After Repeated Failure?

This is where the conversation between marketing and medicine gets uncomfortable. ERA was developed and commercialised by Igenomix, the same company that profits from every test ordered. That does not automatically make the science wrong, but it does mean every study funded or conducted by the company should be read with the same scepticism patients would apply to any product recommendation made by the manufacturer.

• The 2022 JAMA trial: Doyle and colleagues randomised patients to ERA-guided personalised transfer timing versus standard timing, and the ERA group did not have higher live birth rates. That is the single best piece of evidence available on this question, and it went against what the fertility industry had been telling patients for years. A 2023 reanalysis of the same data went further and suggested ERA-guided transfers may have actually reduced outcomes.
• ESHRE said no: The European Society of Human Reproduction and Embryology’s 2023 guidelines on recurrent implantation failure explicitly do not recommend ERA for routine clinical use. When the largest reproductive medicine body in Europe reviews all the evidence and decides against recommending a test, patients deserve to know that before they pay for it.
• Most failures are not timing: The majority of implantation failures after transferring good-quality embryos are caused by chromosomal abnormalities the embryo carried, not by endometrial timing being off by 12 hours. ERA addresses a problem that accounts for a small minority of failures while the dominant cause remains embryo genetics, and patients whose doctor recommends ERA without first ruling out embryo quality through IUI treatment progression or PGT-A are starting with the less likely explanation.
• When ERA might still make sense: Patients who have transferred 3 or more PGT-A tested euploid embryos and none implanted represent the one population where endometrial timing becomes a plausible suspect after embryo quality has been excluded, and for that narrow group the ERA hypothesis is at least logical even if unproven, which is a materially different clinical conversation than offering ERA to everyone after their first or second failed transfer.

The fertility industry has a pattern of adopting tests before the evidence supports them and dropping them quietly years later when the data disappoints. ERA may or may not follow that trajectory, but women managing PCOS and pregnancy alongside recurrent failure deserve a doctor who explains where the evidence currently stands rather than where the marketing brochure says it should be. Any good IVF center in India orders ERA selectively after ruling out embryo quality rather than reflexively after every failed transfer.

Why Choose Dr. Manisha Mehta?

Dr. Manisha Mehta has ordered ERA tests for patients whose clinical picture genuinely warranted investigating endometrial timing and declined to order them for patients whose failure was more plausibly explained by embryo quality, and her 85% IVF success rate reflects a practice where diagnostic tests are ordered to answer a specific clinical question rather than to fill the silence after a failed cycle with activity that feels productive. Recognised among the best IVF specialists in India for evidence-based use of IVF add-ons, she treats ERA as a tool for a specific diagnostic scenario rather than a standard step in every failed-cycle workup.

Call Now: +91 91680 39000